Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Nassief

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?George Nassief, Angela Anaeme, Karen Moussa, et al.
Melanoma Management|December 9, 2025
Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case seriesGeorge Nassief, Renee Morecroft, Jordan Phillipps, et al.
Frontiers in Oncology|August 22, 2025
PARP inhibitors in melanoma treatment: potential, challenges, and future directionsAngela Anaeme, Karen Moussa, Abdallah N Mansour, et al.
International Journal of Molecular Sciences|September 28, 2024
Recent Advancements in Cell-Based Therapies in MelanomaGeorge Nassief, Angela Anaeme, Karen Moussa, et al.
JCO Oncology Practice|May 20, 2026
Payer-Negotiated Prices in the Diagnosis and Management of Cutaneous Melanoma in 2025Michael Y Bian, George Nassief, Victoria Ruesch, et al.
Frontiers in Oncology|May 11, 2026
Immunoembolization in liver-predominant metastatic uveal melanoma: a single-center retrospective analysisRenee Morecroft, Jordan Phillipps, Amrat Kumar, et al.
NPJ Precision Oncology|September 4, 2024
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanomaJordan Phillipps, George Nassief, Renee Morecroft, et al.
Scientific Reports|February 10, 2024
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomesFavour A Akinjiyan, George Nassief, Jordan Phillipps, et al.
JCO Precision Oncology|January 14, 2026
Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient CohortGeorge Nassief, Tolulope Adeyelu, Andrew Elliott, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmaceuticals (Basel, Switzerland)|July 27, 2024
Where Are We Now with Oncolytic Viruses in Melanoma and Nonmelanoma Skin Malignancies?George Nassief, Angela Anaeme, Karen Moussa, et al.
Melanoma Management|December 9, 2025
Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case seriesGeorge Nassief, Renee Morecroft, Jordan Phillipps, et al.
Frontiers in Oncology|August 22, 2025
PARP inhibitors in melanoma treatment: potential, challenges, and future directionsAngela Anaeme, Karen Moussa, Abdallah N Mansour, et al.
International Journal of Molecular Sciences|September 28, 2024
Recent Advancements in Cell-Based Therapies in MelanomaGeorge Nassief, Angela Anaeme, Karen Moussa, et al.
JCO Oncology Practice|May 20, 2026
Payer-Negotiated Prices in the Diagnosis and Management of Cutaneous Melanoma in 2025Michael Y Bian, George Nassief, Victoria Ruesch, et al.
Frontiers in Oncology|May 11, 2026
Immunoembolization in liver-predominant metastatic uveal melanoma: a single-center retrospective analysisRenee Morecroft, Jordan Phillipps, Amrat Kumar, et al.
NPJ Precision Oncology|September 4, 2024
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanomaJordan Phillipps, George Nassief, Renee Morecroft, et al.
Scientific Reports|February 10, 2024
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomesFavour A Akinjiyan, George Nassief, Jordan Phillipps, et al.
JCO Precision Oncology|January 14, 2026
Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient CohortGeorge Nassief, Tolulope Adeyelu, Andrew Elliott, et al.
Pageof 1